C-reactive protein as a biomarker for urological cancers (Q37949270)

25 August 2017

title

C-reactive protein as a biomarker for urological cancers (English)

1 reference

25 August 2017

0 references

Kazutaka Saito

1

1 reference

25 August 2017

Kazunori Kihara

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

25 October 2011

1 reference

25 August 2017

published in

Nature Reviews Urology

1 reference

25 August 2017

volume

8

1 reference

25 August 2017

issue

12

1 reference

25 August 2017

page(s)

659-666

1 reference

Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

An integrated view of humoral innate immunity: pentraxins as a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPβ to the promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein: risk marker or mediator in atherothrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Human C-reactive protein: expression, structure, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell linesin vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Interleukin-6 and renal cell cancer: production, regulation, and growth effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Phase‐II trial of combination treatment of interferon‐α, cimetidine, cyclooxygenase‐2 inhibitor and renin‐angiotensin‐system inhibitor (I‐CCA therapy) for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Role of C-reactive protein as a biomarker for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Pretreatment serum CRP and response to interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Metastatic renal carcinoma comprehensive prognostic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Grading systems in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

High-sensitivity C-reactive protein and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Increased mortality rates in young and middle-aged patients with malignant germ cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

The phenomenon of the acute phase response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

What does minor elevation of C-reactive protein signify?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Appraisal of a model for prediction of prognosis in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Judging New Markers by Their Ability to Improve Predictive Accuracy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Immunotherapy for advanced renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Enhanced Expression of Interleukin-6 in Primary Human Renal Cell Carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

Extremely elevated C-reactive protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2011.145

High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease

31 March 2020

1 reference

12 December 2020

Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro

1 reference

12 December 2020

Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants

1 reference

12 December 2020

Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation

1 reference

12 December 2020

An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2011.145

1 reference

release_y5d53pd4yvddvkn3zcv7ardajm

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y5d53pd4yvddvkn3zcv7ardajm

24 November 2022

mapped directly with Wikidata item

1 reference